Zobrazeno 1 - 10
of 94
pro vyhledávání: '"J A Sosman"'
Autor:
C. Robert, Grant A. McArthur, Ivor Caro, A. Ribas, Shelley Coleman, R. Dummer, Matthew Wongchenko, J.M.G. Larkin, I. Chang, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, David W. Hogg, J. A. Sosman, Axel Hauschild, Y Yan, Paul Lorigan, J.B.A.G. Haanen, Paul B. Chapman, Keith T. Flaherty
Publikováno v:
Melanoma Research. 26:e1-e122
Autor:
Scott N. Gettinger, Ahmad Mokatrin, Daniel S. Chen, Priti S. Hegde, David F. McDermott, Yuanyuan Xiao, Donald P. Lawrence, Leora Horn, F. Stephen Hodi, John D. Powderly, J. A. Sosman, Omid Hamid, Ira Mellman, Jean-Charles Soria, Michael S. Gordon, Marcin Kowanetz, Hartmut Koeppen, Maya Leabman, Roy S. Herbst, Gregg Fine, Sandra Rost, Holbrook E Kohrt
Publikováno v:
Nature. 515:563-567
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing t
Publikováno v:
Urologie Scan. :178-179
Autor:
Anna C. Pavlick, Christian U. Blank, Nageatte Ibrahim, Adil Daud, Dirk Schadendorf, Igor Puzanov, F.S. Hodi, J. A. Sosman, Rene Gonzalez, Antoni Ribas, April K.S. Salama, J. Yang, Omid Hamid, B. Homet Moreno, Jacob Schachter, Lee D. Cranmer, Steven J. O'Day, Kim Margolin, C. Robert, Reinhard Dummer
Publikováno v:
Web of Science
Autor:
Fan Jin, Georgina V. Long, J.S. Weber, Jonathan Cebon, Daniele Ouellet, Michelle T. Ashworth, Kevin B. Kim, Richard F. Kefford, Omid Hamid, Peng Sun, Shonda M Little, J. A. Sosman, Gursel Aktan, Rene Gonzalez, Alexander M. Menzies, Lynn M. Schuchter, Keith T. Flaherty, J. R. Infante, Suzanne Swann, Adil Daud
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 26(2)
Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug e
Autor:
Claus Garbe, C. Robert, Jessie J. Hsu, Ivor Caro, P.A. Ascierto, Matthew Wongchenko, Paul B. Chapman, Antoni Ribas, J. A. Sosman, Grant A. McArthur, James Larkin, Brigitte Dréno, Ilsung Chang, Isabelle Rooney, Michele Maio, Yibing Yan
Publikováno v:
Annals of Oncology. 27:vi379
Autor:
K R, Oettel, O H, Wesly, M R, Albertini, J A, Hank, O, Iliopolis, J A, Sosman, K, Voelkerding, S Q, Wu, S S, Clark, P M, Sondel
Publikováno v:
Blood. 83:3390-3402
Immunocompetent cells in bone marrow allografts have been associated with a graft-versus-leukemia (GVL) effect. To further characterize effector mechanisms that may be involved in this GVL phenomenon, we have previously established an in vitro model
Autor:
Barbara N. Weissman, Piran Aliabadi, Nancy D. Baker, Steven D. Blotner, Richard P. Polisson, Michael E. Weinblatt, J. Leland Sosman
Publikováno v:
Arthritis & Rheumatism. 36:613-619
Objective. To determine the effects of drug therapy (methotrexate [MTX] versus auranofin [AUR]) on radiographic progression in patients with active rheumatoid arthritis (RA). Methods. We conducted a 9-month randomized, multicenter, double-blind trial
Autor:
J. A. Sosman, Clive Morris, Mireille Cantarini, C. Robert, John M. Kirkwood, R. Dummer, Lars Bastholt, Mark R. Middleton, K Kemsley, Paul B. Chapman
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY. 26(15)
9033 Background: AZD6244 is an orally available, potent, selective, ATP uncompetitive inhibitor of MEK1/2, with preclinical and phase I data suggesting it has the potential for anti-tumor activity in pts with melanoma. Here we evaluate the efficacy a
Autor:
John Wagstaff, T. Ueda, Giuseppe Procopio, Howard Gurney, Hans J. Hammers, Elizabeth R. Plimack, Daniel Castellano, Ian M. Waxman, Petri Bono, Padmanee Sharma, David F. McDermott, Thomas Gauler, Scott S. Tykodi, Frede Donskov, Robert J. Motzer, Li-an Xu, Saby George, Bernard Escudier, J. A. Sosman, Sandhya Srinivas
Publikováno v:
European Journal of Cancer. 51:S708
with the nominal cost model, amounting to US$16.9 billion in 2015−35 (−US$14.9 billion in LIC; −US$18.7 billion LMIC, and US$50.5 billion in UMIC). The returns with the efficiency model were projected to be greater, however, amounting to US$104